Indirect effects of doxyPEP implementation reveal core-group dynamics of bacterial sexually-transmitted infections
Authors:
Preprint
Abstract
Epidemiological theory holds that core groups of high-risk individuals sustain pathogen transmission. However, the scale at which these dynamics operate is poorly understood. We leveraged doxycycline post-exposure prophylaxis (doxyPEP) implementation among at-risk men who have sex with men (MSM) and transgender women (TGW) as a natural experiment to probe bacterial sexually transmitted infection (STI) dynamics within and across sexual networks. DoxyPEP uptake by 9% of at-risk MSM and TGW was associated with pronounced indirect protection within their sexual networks, substantiating the notion that core groups of individuals wield outsize influence on transmission. Risk of chlamydia and syphilis declined by 80% (95% confidence interval: 71-86%) and 65% (30-82%), respectively, among doxyPEP recipients, and by 41% (32-48%) and 29% (13-42%), respectively, among MSM and TGW who did not receive doxyPEP. However, this substantial reduction in disease among at-risk MSM and TGW did not impact incidence among females and other males. Our findings substantiate core group dynamics of STIs among MSM and TGW but call into question the "bisexual bridge" hypothesis positioning this population as a core group impacting STI dynamics among heterosexuals. These findings should inform rational expectations for the impacts of doxyPEP in settings implementing this intervention.Keywords
Funding Information
- US Centers for Disease Control & Prevention (CDC-RFA-FT-230069)
This publication has 31 references indexed in Scilit:
- Impact of doxycycline post-exposure prophylaxis on Neisseria gonorrhoeae antimicrobial resistance to doxycycline and ceftriaxone in Milan, ItalyClinical Microbiology and Infection, 2026
- Durability of doxycycline effectiveness against gonorrhoea after implementation of post-exposure prophylaxis in southern California, USA: a retrospective, test-negative, observational studyThe Lancet Infectious Diseases, 2026
- Impact and cost-effectiveness of doxycycline post-exposure prophylaxis in Australian men who have sex with menNature Communications, 2026
- Bacterial sexually transmitted infections and related antibiotic use among individuals eligible for doxycycline post-exposure prophylaxis in the United StatesNature Communications, 2025
- Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection TrendsJAMA Internal Medicine, 2025
- Doxycycline Postexposure Prophylaxis and Bacterial Sexually Transmitted Infections Among Individuals Using HIV Preexposure ProphylaxisJAMA Internal Medicine, 2025
- Effects of doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections on gonorrhoea prevalence and antimicrobial resistance among men who have sex with men in the USA: a modelling studyThe Lancet Microbe, 2024
- Syphilis testing, incidence, and reinfection among gay and bisexual men in Australia over a decade spanning HIV PrEP implementation: an analysis of surveillance data from 2012 to 2022The Lancet Regional Health - Western Pacific, 2024
- Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial designThe Lancet Infectious Diseases, 2024
- Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trialThe Lancet Infectious Diseases, 2018